Prospective evaluation of the drug-metabolizing enzyme polymorphisms and toxicity profile of docetaxel in Korean patients with operable lymph node-positive breast cancer receiving adjuvant chemotherapy.

Abstract excerpt

BACKGROUND: Inter-individual variability of pharmacokinetics may account for unpredictable toxicities of docetaxel. METHODS: From March 2007 to June 2008, female patients with operable lymph node-positive breast cancer receiving docetaxel-containing adjuvant chemotherapy were included in this study. The 4 cycles of planned dose of docetaxel (100 mg/m(2)) was performed as adjuvant chemotherapy, following 4 cycles...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Chemotherapy, Adjuvant
• Share to Cyclophosphamide